ClinicalTrials.gov
ClinicalTrials.gov Menu

Exploring the Effects of Diazepam and Lorazepam (ibid)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00696033
Recruitment Status : Completed
First Posted : June 12, 2008
Last Update Posted : September 17, 2009
Sponsor:
Information provided by:
University Hospital, Strasbourg, France

Brief Summary:

Aims :

  • exploring lorazepam (0.038 mg/kg) effects, after a single oral intake, in healthy volunteers, on the neural correlates of encoding and retrieval of information during a word-stem completion task (implicit memory), using fMRI
  • comparing lorazepam effects to diazepam (0.3 mg/kg)effects
  • exploring benzodiazepines effects, after a single oral intake, on the neural correlates of successful encoding of information within explicit memory using fMRI

Hypothesis :

  • both diazepam and lorazepam will impair explicit memory performance, but lorazepam only will impair perceptual priming
  • lorazepam and diazepam will modify the normal correlates of information encoding within explicit memory
  • lorazepam only will alter the neural correlates of perceptual priming

Condition or disease Intervention/treatment Phase
Healthy Subjects Drug: Diazepam Drug: Lorazepam Drug: placebo Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 22 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Official Title: Exploring the Effects of Diazepam and Lorazepam on the Neural Correlates of Perceptual Priming and Explicit Memory in Healthy Volunteers
Study Start Date : July 2007
Actual Primary Completion Date : December 2008
Actual Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Memory
U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1
Oral Lorazepam
Drug: Lorazepam
Lorazépam drug (0,038 mg/kg) on a single oral intake
Experimental: 2
Oral Diazepam
Drug: Diazepam
Diazépam drug (0,3 mg/kg) on a single oral intake
Placebo Comparator: 3
Oral placebo
Drug: placebo
lorazépam placebo or Diazépam placebo



Primary Outcome Measures :
  1. Exploring lorazepam (0.038 mg/kg) effects, after a single oral intake, in healthy volunteers, on the neural correlates of encoding and retrieval of information during a word-stem completion task (implicit memory), using fMRI [ Time Frame: After a single oral intake ]

Secondary Outcome Measures :
  1. Comparing lorazepam effects to diazepam (0.3 mg/kg)effects [ Time Frame: After a single oral intake ]
  2. Exploring benzodiazepines effects, after a single oral intake, on the neural correlates of successful encoding of information within explicit memory using fMRI [ Time Frame: After single oral intake ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 30 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy subjects between 18 and 30 years
  • Students in medicine, dentistry or pharmacy
  • French as a mother language

Exclusion criteria:

  • Medical condition influencing brain function (neurological or psychiatric)
  • Asthma
  • General anesthesia in the 3 last months
  • Drug addiction (DSM IV criteria)
  • Regular medical treatment (except contraceptive pill)
  • Significant impairment observed during a medical examination including ECG
  • Intake of any psychotropic drug that can have a effect during testing
  • IQ (Wechsler) < 100
  • FMRI contra-indication (implantable magnetic material, claustrophobia)
  • Known allergy to benzodiazepine or lactose
  • > 10 cigarettes/day
  • Pregnant or breast-feeding woman
  • No health insurance
  • Subjects who do not complete the entire study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00696033


Locations
France
Centre d'investigation clinique, hôpital civil
Strasbourg, France, 67091
Clinique psychiatrique, hôpital civil
Strasbourg, France, 67091
Sponsors and Collaborators
University Hospital, Strasbourg, France
Investigators
Principal Investigator: Pierre Vidailhet, MD Hôpitaux universitaires de strasbourg

Responsible Party: Christine GEILLER, directeur Adjoint, University Hospital, Strasbourg, France
ClinicalTrials.gov Identifier: NCT00696033     History of Changes
Other Study ID Numbers: 3777
First Posted: June 12, 2008    Key Record Dates
Last Update Posted: September 17, 2009
Last Verified: September 2009

Keywords provided by University Hospital, Strasbourg, France:
Benzodiazepines
Lorazepam
Diazepam
Memory
Perceptual priming
Functional brain imaging
FMRI

Additional relevant MeSH terms:
Lorazepam
Diazepam
Anticonvulsants
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hypnotics and Sedatives
Central Nervous System Depressants
Anti-Anxiety Agents
Tranquilizing Agents
Psychotropic Drugs
GABA Modulators
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adjuvants, Anesthesia
Muscle Relaxants, Central
Neuromuscular Agents
Anesthetics, Intravenous
Anesthetics, General
Anesthetics